Quantinno Capital Management LP raised its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Free Report) by 24.2% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 8,312 shares of the company’s stock after buying an additional 1,622 shares during the period. Quantinno Capital Management LP’s holdings in BeOne Medicines were worth $2,469,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of the stock. EFG International AG acquired a new stake in BeOne Medicines during the fourth quarter worth about $25,000. Daiwa Securities Group Inc. purchased a new stake in BeOne Medicines in the 2nd quarter worth approximately $35,000. Leonteq Securities AG acquired a new stake in shares of BeOne Medicines during the 4th quarter worth approximately $35,000. CWM LLC grew its stake in shares of BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares during the period. Finally, Group One Trading LLC purchased a new position in shares of BeOne Medicines during the 4th quarter valued at approximately $61,000. Institutional investors and hedge funds own 48.55% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on ONC. Citigroup reissued an “outperform” rating on shares of BeOne Medicines in a report on Thursday. Morgan Stanley reaffirmed an “overweight” rating on shares of BeOne Medicines in a report on Thursday. Truist Financial upped their price objective on shares of BeOne Medicines from $416.00 to $418.00 and gave the stock a “buy” rating in a research report on Thursday. Barclays increased their target price on shares of BeOne Medicines from $403.00 to $407.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Wells Fargo & Company began coverage on BeOne Medicines in a research note on Monday, May 4th. They issued an “overweight” rating and a $400.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $400.00.
BeOne Medicines Stock Performance
ONC opened at $348.27 on Monday. The firm’s fifty day simple moving average is $296.52 and its two-hundred day simple moving average is $308.69. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $253.95 and a 52-week high of $385.22. The company has a market cap of $38.21 billion, a price-to-earnings ratio of 61.32 and a beta of 0.49. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17.
BeOne Medicines (NASDAQ:ONC – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.65. The business had revenue of $1.71 billion during the quarter, compared to analysts’ expectations of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. Equities analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 7.3 earnings per share for the current fiscal year.
Insider Activity at BeOne Medicines
In other BeOne Medicines news, COO Xiaobin Wu sold 1,484 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $269.37, for a total value of $399,745.08. Following the transaction, the chief operating officer owned 40 shares in the company, valued at approximately $10,774.80. This trade represents a 97.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John Oyler sold 145,861 shares of the company’s stock in a transaction on Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95. Following the sale, the chief executive officer directly owned 8,122 shares of the company’s stock, valued at $2,484,925.90. The trade was a 94.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 345,561 shares of company stock worth $105,625,947. Company insiders own 6.19% of the company’s stock.
Trending Headlines about BeOne Medicines
Here are the key news stories impacting BeOne Medicines this week:
- Positive Sentiment: Strong Q2 performance: BeOne reported adjusted earnings of $2.05 per share, topping the $1.40 consensus estimate, while revenue reached $1.71 billion versus expectations of $1.66 billion. The earnings beat reinforces confidence in the company’s oncology portfolio and profitability. BeOne Medicines Q2 earnings report
- Positive Sentiment: 2026 outlook raised: Management increased its full-year revenue forecast to approximately $6.6 billion-$6.8 billion, above Wall Street’s prior estimate of $6.5 billion, citing a 30% quarterly revenue surge. BeOne Medicines raises 2026 outlook
- Positive Sentiment: Analyst targets moved higher: TD Cowen raised its target to $454 and assigned a Buy rating; Guggenheim increased its target to $430, Truist lifted its target to $418, and Citizens JMP raised its target to $405. RBC made a modest reduction to $450 but retained an Outperform rating. Collectively, the updates indicate substantial implied upside from recent trading levels. Analyst price-target updates
- Positive Sentiment: Institutional buying: Bank of America, Man Group, BNP Paribas and other institutions recently established or expanded positions, suggesting continued professional-investor interest in ONC.
- Neutral Sentiment: Insider sale was tax-related: CFO Aaron Rosenberg sold 1,157 shares valued at about $362,000 to cover tax withholding from vested equity awards. The transaction is therefore a limited bearish signal. SEC insider transaction filing
- Negative Sentiment: Valuation risk: With a high earnings multiple and the stock trading below its 52-week high, investors may require continued rapid growth and execution to justify the current valuation.
BeOne Medicines Profile
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Featured Articles
- Five stocks we like better than BeOne Medicines
- Albemarle’s Blowout Quarter Shows Why Lithium Still Matters
- Can DICK’S Turn Foot Locker Into a Winner?
- Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
